Researchers at Oregon State University have engineered a nanomaterial that triggers two separate chemical reactions inside cancer cells, essentially turning the tumor's own chemistry against itself. In mice with breast cancer, the treatment eliminated tumors completely without harming surrounding tissue or causing systemic side effects.
The breakthrough builds on a strategy called chemodynamic therapy, which exploits a fundamental difference between cancer and healthy cells: tumors are more acidic and contain higher levels of hydrogen peroxide. Scientists have long known these conditions exist. The challenge has been weaponizing them effectively.
How the two-pronged attack works
Traditional chemodynamic approaches generate hydroxyl radicals — highly reactive molecules that damage cancer cells by breaking down their lipids, proteins, and DNA. More recent versions added a second weapon: singlet oxygen, another reactive compound that's particularly destructive inside cells.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThe problem, according to researcher Oleh Taratula, was that existing treatments could do one or the other well, but not both. "They efficiently generate either radical hydroxyls or singlet oxygen but not both, and they often lack sufficient catalytic activity to sustain robust reactive oxygen species production," he explained. "Preclinical studies often only show partial tumor regression."
The new nanomaterial — an iron-based metal-organic framework, or MOF — generates both reactive compounds simultaneously with superior efficiency. In lab tests across multiple cancer cell lines, it proved potent against cancer while showing negligible harm to healthy cells.
When the team administered the nanoagent intravenously to mice bearing human breast cancer cells, it accumulated directly in tumors and generated reactive oxygen species robustly enough to eradicate the cancer completely. The mice showed total tumor regression, long-term prevention of recurrence, and no systemic toxicity.
Before human trials can begin, the researchers plan to test the treatment against other cancer types, including aggressive pancreatic cancer, to establish whether this approach works broadly across different malignancies. That work will determine whether this lab success translates into a meaningful option for patients facing cancers that have historically been difficult to treat.
Study: "Structurally Engineered Ferrous Metal–Organic Framework as a Chemodynamic Therapy Nanoagent for Concurrent Hydroxyl Radical and Singlet Oxygen Generation" — Advanced Functional Materials, 2026
